Defense Health Agency Issues New Authority to GlobalMed

Authority to Operate enables all Defense Health Agency locations to purchase and utilize GlobalMed's Virtual Health Technologies

GlobalMed, an international provider of telehealth solutions, today announced that its industry leading virtual health platform has earned the Defense Health Agency (DHA) Authority to Operate (ATO) on the U.S. Department of Defense (DoD) DHA Medical Community of Interest (Med COI) network.

GlobalMed’s virtual health solutions are the first synchronous clinical virtual health technologies awarded an ATO. This much coveted certification enables GlobalMed to integrate their virtual health platform including carts, medical devices, software, and applications directly with the DHA’s Med COI network, making their solutions available to integrate with MHS Genesis, the new patient-centric enterprise system designed to provide a single, continuous record of care for all DOD beneficiaries. In addition to providing medical care on the battlefield and at bases overseas (as well as on ships) DHA’s network includes 721 military treatment facilities and 174,000 health care personnel, which provide health services to approximately 9.6 million beneficiaries.

“It has always been a personal priority to increase health care access for the members and families of the Army, Navy, Air Force, Marines, Space Force and Coast Guard,” said Joel E. Barthelemy, CEO and Vice Chairman of GlobalMed and a Marine Corps Reserve Veteran. “The Department of Defense is a huge healthcare provider and network security is a high priority. GlobalMed is committed to every aspect of security and compliance throughout our applications having recently completed our SOC 2 Type 2 examination with even more stringent security attestations on our road map. Our commitment to delivering unmatched performance, security and scalability extends beyond our government clients to those in the commercial enterprise space, giving physician groups and non-government hospitals an added measure of reassurance.”

DHA selected GlobalMed for its HIPAA-compliant virtual telemedicine platform that seamlessly and securely connects healthcare professionals and patients, regardless of location. GlobalMed is also the telehealth provider for the White House Medical Unit and has deployed their solutions across the VA hospitals and extension centers, and other U.S. Departments and Agencies.

SourceGlobalMed
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version